France's Poxel Q1 revenue rises 20% on TWYMEEG sales

Poxel SA

20/05/2026 07:11

Overview

France biopharma firm's Q1 2026 revenue rose 20% yr/yr to €1.277 mln

Growth driven by 36% increase in TWYMEEG net sales in Japan

Company expanded TWYMEEG prescribing info for patients with renal impairment in Japan

Outlook

Sumitomo Pharma expects moderate double-digit growth slightly above 10% in TWYMEEG sales for FY 2026

Sumitomo Pharma expects TWYMEEG net sales to exceed JPY 10 bln in FY 2026

Poxel expects to receive 12% royalties and a JPY 1 bln milestone payment if sales exceed JPY 10 bln

Result Drivers

TWYMEEG SALES GROWTH - Q1 revenue growth driven by 36% increase in TWYMEEG net sales in Japan

RENAL IMPAIRMENT LABEL EXPANSION - Regulatory approval enabled promotion of TWYMEEG for patients with renal impairment, expanding eligible population

Company press release: ID:nBwbn9Z5Ka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 1.28 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)